Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.50 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL583097 | 1.00 | TAAR1 (0.58) | TAAR1AOC3TRPA1RIPK1KDM4E | |
| SCHEMBL8159872 | 1.00 | TAAR1 (0.58) | TAAR1AOC3TRPA1RIPK1KDM4E | |
| SCHEMBL27548676 | 0.87 | TAAR1 (0.47) | TAAR1AOC3TRPA1RIPK1KDM4E | |
| SCHEMBL11755433 | 0.86 | GRIA4 (0.50) | TAAR1AOC3ALDH1A1 | |
| SCHEMBL11024335 | 0.86 | ESR1 (0.41) | TAAR1AOC3TRPA1RIPK1 | |
| SCHEMBL29224030 | 0.83 | TRPA1 (0.67) | TAAR1AOC3TRPA1RIPK1KDM4E | |
| SCHEMBL11024645 | 0.82 | HDAC4 (0.41) | TAAR1AOC3TRPA1RIPK1KDM4E | |
| SCHEMBL1553853 | 0.80 | RIPK1 (0.57) | TAAR1AOC3TRPA1RIPK1 | |
| SCHEMBL6280516 | 0.78 | RIPK1 (0.67) | TAAR1AOC3TRPA1RIPK1 | |
| SCHEMBL3672929 | 0.78 | TRPA1 (0.67) | TAAR1AOC3TRPA1RIPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| WO-2008119772-A1 | AMIDE DERIVATIVES AS INHIBITORS OF ASPARTYL PROTEASES | MEDIVIR AB (SE) | 2008-10-09 | — | — | WO | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | SHIONOGI & CO., LTD. (JP) | 2007-02-01 | — | — | US | disclosed |
| EP-0784050-B1 | Novel aspartylamide derivatives and sweeteners | AJINOMOTO KK (JP) | 2001-10-04 | — | — | EP | disclosed |
| US-6010733-A | ARTIFICIAL SWEETENER | AJINOMOTO CO., INC. (JP) | 2000-01-04 | — | — | US | disclosed |
| EP-0784050-A1 | Novel aspartylamide derivatives and sweeteners | Ajinomoto Co., Inc. (JP) | 1997-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027144-A1 | Novel use of cannabinoid receptor agonist | CNR2, CNR1, OPRM1 | TAAR1 569/4885AOC3 880/4885TRPA1 326/4885 |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | TAAR1 174/4885AOC3 1424/4885TRPA1 919/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | TAAR1 203/4885AOC3 3019/4885TRPA1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.